DexCom is trading at $78.51 (+5.33%) after reporting a strong second quarter and lifting full-year 2026 guidance.
- Q2 revenue rose 13% to $1.308 billion with GAAP EPS of $0.64.
- The company noted margin expansion and an upgraded outlook, which served as a clear catalyst alongside a broader post-close risk-on tape.